Protalix BioTherapeutics

Protalix BioTherapeutics

Protalix BioTherapeutics

Protalix BioTherapeutics, a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system.
Raised
$43.7M
Follow us
Latest funding
$43,700,000
Private equity - 2020
Highbridge Capital Management Psagot Investment House More Investment House +3
Team Size
1–10
Employees
Location
Headquarters
$43,700,000 Private equity
FinSMEs

Protalix BioTherapeutics Raises $43.7M in Financing